TL938 not checked

Teligene US

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Colorectal Cancer Metastatic, Advanced Colorectal Cancer
Main trialPhase 2
“This Phase 2 study evaluates TL938 alone or in combination with trastuzumab in patients with HER2-positive advanced colorectal cancer. Cohort 1 determines the recommended Phase 2 dose of TL938 with trastuzumab. Cohorts 2 and 3 evaluate the efficacy and safety of TL938 with trastuzumab or TL938 alone at that dose.”In the company’s words, NCT06589830 on ClinicalTrials.gov

Other drugs for Colorectal Cancer Metastatic

All 392 drugs for Colorectal Cancer Metastatic

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Dec 2028 TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow TL938

Following is part of Solo: you see every change to TL938 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in